Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple dye test spot kidney trouble in the ICU?

NCT ID NCT02050269

Diagnosis Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a dye called iohexol can accurately measure kidney function in 100 ICU patients with unstable blood pressure. The goal was to see if this method could help detect acute kidney injury earlier than current tests. Researchers tracked how quickly the dye cleared from the blood and compared it to other kidney injury markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Iohexol (a contrast dye)
What this could lead to
If successful, this could provide a more accurate way to measure kidney function in critically ill patients, helping doctors detect kidney injury earlier.
What could go wrong
This is a small feasibility study, not a treatment trial. The method may not be practical or accurate enough for routine ICU use, and iohexol carries a small risk of allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

100 people

The number who actually took part.

Start date

Jan 2014

Finished

Jun 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Patient admitted to intensive care for less than 12 hours * Acute circulatory failure * Patient carrying an arterial catheter * Informed consent obtained * Affiliated to social security system Exclusion Criteria: * Administration of iohexol the week before intensive care admission * Administration of iohexol expected within 24 hours of study entry * Known history of cutaneous immediate or delayed allergic reaction to the injection of the product * Indication for albumin transfusion within 24 hours of potential inclusion in the study * Pregnancy or breastfeeding in progress * Patient under guardianship or judicial protection known at the time of inclusion * Withdrawal of consent * Administration of iohexol outside the study within 24 hours after administration of iohexol in the context of the study * Administration of intravenous albumin in the 24 hours following administration of iohexol in the context of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute circulatory failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Shock

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute circulatory failure

Contacts and locations

Locations

  • Hospital La SOURCE

    Orléans, 45000, France

  • Service de Réanimation Polyvalente, CHRU de Tours

    Tours, 37044, France

  • University Hospital Strasbourg

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.